




I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, PO Box 1450, Alexandria VA, , on the date shown below.

Dated: March 2, 2004

Signature:



Katherine L. Neville

Docket No.: 27866/37524
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gallatin et al

Application No.: 09/891,943

Group Art Unit: 1644

Filed: June 26, 2001

Examiner: P. Gambel

For: Novel Human Beta-2 Integrin Alpha subunit

RESPONSE TO FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.111

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This paper is in response to an outstanding Final Office Action (hereinafter, the "Office Action"), mailed November 5, 2003, in the above-mentioned application. In the Office Action, the examiner rejected claims 11-14 under 35 U.S.C. § 112, first paragraph, for asserted lack of enablement and under 35 U.S.C. §112, second paragraph, for asserted indefiniteness. The Examiner also rejected claims 11-14 under 35 U.S.C. 102 (b) as allegedly being anticipated by Gallatin *et al.*, US Patent No. 5,437,958 (hereinafter "Gallatin").

A Notice of Appeal accompanies this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 3 of this paper.